Download pdf
Mechanism of mRNA vaccine, current study and direction of development
- 1 University of Shanghai for Science and Technology
* Author to whom correspondence should be addressed.
Abstract
Following the COVID-19 outbreak, two mRNA vaccines were marketed in late 2020 after receiving FDA-approved emergency access, pioneering the use of mRNA vaccines in humans. Since then, more and more companies have joined the development and clinical trials of mRNA vaccines. At this stage, the development of mRNA vaccines is not only limited to COVID-19, but also covers infectious diseases, influenza, and cancer. Up to now, the regulation of immunogenicity of mRNA vaccines is a problem to be solved, and the controversy is mainly about typeⅠIFN. This paper mainly introduces the classification, mechanism and characteristics of mRNA vaccines to show the basic principle of mRNA vaccines, and lists the applications of mRNA vaccines and the types of vaccines that are undergoing clinical trials, which reflects their huge application potential. The potential of mRNA vaccines is shown. With this paper, the author summarizes the current status of mRNA vaccines in order to show readers the basic principles and potentials of mRNA vaccines.
Keywords
mRNA vaccine, mechanism, application
[1]. Negahdaripour M & Ghasemi Y 2022 Witnessing a revolution in the vaccinology field: A thought on its probable impact on future vaccines Trends Pharm Sci 8 2 67-68
[2]. Pardi N Hogan M J & Weissman D 2020 Recent advances in mRNA vaccine technology Curr Opin Immunol 65 14-20
[3]. Wang Y Zhang Z Luo J et al 2021 mRNA vaccine: A potential therapeutic strategy Mol Cancer 20 33
[4]. Wang Y S Kumari M Chen G H et al 2023 mRNA-based vaccines and therapeutics: An in-depth survey of current and upcoming clinical applications J Biomed Sci 30 84
[5]. Chen Y & Sun Y 2021 Progress in mRNA vaccine—The 2021 Lasker Clinical Medicine Research Award J Capital Med Univ 42 5 893-889
[6]. Xu S Yang K Li R & Zhang L 2020 mRNA vaccine era—Mechanisms drug platform and clinical prospection Int J Mol Sci 21 18 6582
[7]. Yang J Xiao L J & Fang T W 2024 Research strategies and prospects for tuberculosis mRNA vaccines Chin J Tuberc Dis 05 590-595
[8]. Linares-Fernández S Lacroix C Exposito J-Y & Verrier B 2019 Tailoring mRNA vaccine to balance innate/adaptive immune response Trends Mol Med
[9]. Pepini T Pulichino A-M Carsillo T Carlson A L Sari-Sarraf F Ramsauer K … Iavarone C 2017 Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: Implications for vaccine design J Immunol 198 10 4012-4024
[10]. Kranz L M Diken M Haas H et al 2016 Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy Nature 534 7607 396-401
[11]. Park J W Lagniton P N Liu Y & Xu R H 2021 mRNA vaccines for COVID-19: What why and how Int J Biol Sci 17 6 1446
[12]. Wang B Pei J Xu S Liu J & Yu J 2023 Recent advances in mRNA cancer vaccines: Meeting challenges and embracing opportunities Front Immunol 14 1246682
Cite this article
Wang,K. (2024). Mechanism of mRNA vaccine, current study and direction of development. Theoretical and Natural Science,48,28-33.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 2nd International Conference on Environmental Geoscience and Earth Ecology
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).